Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of mannatide + CAPOX + tislelizumab as first-line treatment for recurrent or metastatic gastric/GEJ adenocarcinoma
ChiCTR2600132223Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mannatide, tislelizumab, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
mannatidetislelizumabcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600132223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132223.